Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONARK: Lopinavir/Ritonavir Monotherapy in HIV
NCT00234923Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Aug 2003
- Primary completion
- Feb 2007
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of lopinavir + ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Antiviral efficacy by HIV RNA at 48 weeks. Started Aug 2003; status: completed.
02
Drugs
lopinavir + ritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00234923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00234923.